Axsome vs. Teva: DXM/Bupropion Patent Consolidation in CNS Drug Litigation

Case Overview

The Parties

The Patent at Issue

This landmark case involves U.S. Patent No. 12,146,889 (Application No. 18/494,550), covering formulations and/or methods related to dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets. The ‘889 patent is among a growing portfolio Axsome has asserted to protect Auvelity®’s market exclusivity in the MDD therapeutic space.

• • US 12,146,889 — Formulations/methods for DXM/Bupropion extended-release tablets

Litigation Timeline & Procedural History

The litigation unfolded in deliberate waves — a hallmark of sophisticated pharmaceutical patent enforcement strategy:

• May 28, 2024: Axsome and Antecip filed Civil Action No. 24-6489 against Teva in the District of New Jersey.
• June 3, 2024: Plaintiffs filed an Amended Complaint in the same action.
• September 30, 2024: Plaintiffs filed related Civil Action No. 24-9535 against Teva.
• October 23, 2024: The Court consolidated Civil Action Nos. 24-6489 and 24-9535.
• December 5, 2024: The Court issued a Pretrial Scheduling Order for the consolidated action, and Plaintiffs simultaneously filed Civil Action No. 24-10938, asserting the newly issued ‘889 patent.
• January 7, 2025: The Court consolidated Civil Action No. 24-10938 into the existing consolidated action, administratively terminating it and centralizing all proceedings under Case No. 24-6489.

The 33-day lifespan of Case No. 24-10938 reflects not a failure but a successful procedural maneuver — a rapid integration of a new patent into live litigation already governed by an operative scheduling order.

The Verdict & Legal Analysis

Outcome

Civil Action No. 24-10938 was administratively terminated by consolidation order on January 7, 2025. The case did not reach a merits determination. All claims, including infringement allegations under the ‘889 patent, are now prosecuted within the consolidated proceeding under Civil Action No. 24-6489. No damages were assessed and no injunctive relief was independently granted in this action.

Consolidation as Litigation Architecture

The Court’s consolidation order serves multiple strategic and administrative functions that merit careful analysis:

Efficiency and Judicial Economy: By consolidating discovery, case management, and trial across all related actions, the Court eliminates duplicative proceedings, reduces costs, and ensures consistent rulings on overlapping factual and legal issues — particularly claim construction determinations that will govern all asserted patents.

Rolling Patent Assertion: Axsome’s filing of a new action on the same day the Court issued a scheduling order for the earlier consolidated case — and immediately seeking to fold that new case into the existing framework — illustrates a sophisticated “rolling assertion” strategy. As new patents issue from prosecution (here, the ‘889 patent with application number 18/494,550), rights holders can rapidly integrate them into live ANDA litigation without resetting the litigation clock. Patent attorneys advising branded pharmaceutical clients should note this model as a proven mechanism for expanding infringement claims without procedural disruption.

Teva’s Cooperative Posture: Teva waived formal service on the new complaint and jointly requested consolidation, suggesting the parties recognized mutual benefits in streamlining proceedings. This cooperative posture does not imply any concession on the merits but reflects experienced litigants efficiently managing multi-front litigation.

Legal Significance

The consolidation of three separately filed civil actions into a single proceeding raises important questions that will be resolved in the underlying case:

• Claim Construction: The December 5, 2024 Pretrial Scheduling Order will govern Markman proceedings across all asserted patents. How the Court construes key claim terms in the ‘889 patent — particularly those defining the extended-release formulation — will be pivotal.
• Validity Landscape: Teva, as a sophisticated ANDA filer, is expected to raise invalidity defenses including obviousness under 35 U.S.C. § 103 and potential written description challenges under § 112, particularly given the relatively recent issuance of the ‘889 patent.
• 30-Month Stay Mechanics: Under Hatch-Waxman, ANDA patent litigation triggers a statutory 30-month stay of FDA approval. The multiple filing dates here suggest Axsome is managing patent term expirations and stay periods strategically across its Auvelity® patent portfolio.

Strategic Takeaways

For Patent Holders: Maintain active prosecution of continuation and continuation-in-part applications covering commercial products. Newly issued patents can be asserted rapidly in ongoing ANDA litigation and consolidated without procedural penalty, extending the effective defensive perimeter around a branded product.

For Accused Infringers: Seek early consolidation of all related actions to contain discovery costs, avoid inconsistent rulings, and establish a single, unified claim construction record. Cooperative consolidation motions, as demonstrated by Teva here, can reduce litigation burden without compromising substantive defenses.

For R&D Teams: Monitor competitor patent prosecution activity at the USPTO continuously. Axsome’s issuance of the ‘889 patent mid-litigation — and immediate assertion thereof — underscores that freedom-to-operate (FTO) analyses for generic product development must account for pending continuation applications, not merely issued patents.